7 research outputs found

    Platinum-free, graphene based anodes and air cathodes for single chamber microbial fuel cells.

    Get PDF
    Microbial fuel cells (MFCs) exploit the ability of microorganisms to generate electrical power during metabolism of substrates. However, the low efficiency of extracellular electron transfer from cells to the anode and the use of expensive rare metals as catalysts, such as platinum, limit their application and scalability. In this study we investigate the use of pristine graphene based electrodes at both the anode and the cathode of a MFC for efficient electrical energy production from the metabolically versatile bacterium Rhodopseudomonas palustris CGA009. We achieve a volumetric peak power output (PV) of up to 3.51 ± 0.50 W m-3 using graphene based aerogel anodes with a surface area of 8.2 m2 g-1. We demonstrate that enhanced MFC output arises from the interplay of the improved surface area, enhanced conductivity, and catalytic surface groups of the graphene based electrode. In addition, we show a 500-fold increase in PV to 1.3 ± 0.23 W m-3 when using a graphene coated stainless steel (SS) air cathode, compared to an uncoated SS cathode, demonstrating the feasibility of a platinum-free, graphene catalysed MFCs. Finally, we show a direct application for microwatt-consuming electronics by connecting several of these coin sized devices in series to power a digital clock

    Risk of COVID-19 after natural infection or vaccinationResearch in context

    No full text
    Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health
    corecore